If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
123
results.
Updated on
06/08/2025 [06:55:00]
Results 50 to 75 of 123
Absstract of: WO2025147163A1
The present disclosure relates to an artificial intelligence-based apparatus and method for pancreatic frozen section examination and diagnosis. The apparatus comprises: a memory; and a processor including an artificial intelligence engine for the pancreatic frozen section examination and diagnosis, wherein the processor can acquire a first frozen section image of the pancreas, acquire a second frozen section image corresponding to the first frozen section image of the pancreas, and generate and provide a diagnosis result for the pancreatic frozen section examination on the basis of the first frozen section image and the second frozen section image by using the artificial intelligence engine.
Absstract of: WO2025146479A1
Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time- correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.
Absstract of: CN119731745A
Systems and methods for determining a glucose value of a user are disclosed herein. The method includes: receiving a plurality of data inputs associated with biometric data of a user, the plurality of data inputs including at least one data input representing past estimated glucose values of the user; and processing the plurality of data inputs with a multi-head temporal convolutional neural network to generate a blood glucose value for the user. The method further includes providing a notification to the user based at least in part on the blood glucose value.
Absstract of: WO2025143904A2
Disclosed is an RF biosensing system using an RF sensor including a glucose-responsive hydrogel-based microneedle. The RF biosensing system measures a sensing signal with a VNA by detecting a sensing signal by using a reader antenna and a reader antenna sensing circuit through a readout coil on the basis of RF biosensing and wireless transmission, via EM coupling between a glucose-responsive hydrogel-based microneedle, which is provided below a flexible substrate so as to be minimally invasively applied in vivo to the skin surface (on-site) of epidermis/dermis/hypodermis of the skin or to skin/fat/muscle tissue, and an RF sensor, which is positioned over the flexible substrate and uses the difference in resonant frequencies within frequencies of 400 to 3,000 MHz, and performs biosensing such as detection of proteins, glucose, and fat in the skin, on the basis of changes in the capacitance of a sensing antenna circuit (LC resonator) of the RF sensor, shifts in resonant frequencies of the LC resonator, and changes in S-parameters.
Absstract of: WO2025141628A1
This blood glucose level measurement device comprises: a sensor unit that measures the blood glucose level of a user; a communication unit that transmits, to the outside, data representing the blood glucose level measured by the sensor unit; a flexible, sheet-shaped battery that supplies power to the sensor unit and the communication unit; a flexible, plate-shaped circuit unit that controls the operation of the communication unit; and a mounting unit that is configured to be mounted on the body of the user. The peak current of the battery is 20 mA or more.
Absstract of: AU2025204350A1
Peritoneal dialysis, such as automated peritoneal dialysis (“APD”) is provided with any one or more or all of the following sensing or feedback features: impedance sensing to detect peritonitis, temperature sensing to detect peritonitis, bio-MEMS sensing to detect peritonitis, and glucose control for diabetes patients, wherein each sensing or feedback feature analyzes patient effluent fluid or fluid dwelling within a patient’s peritoneal cavity. Peritoneal dialysis, such as automated peritoneal dialysis ("APD") is provided with any one or more or all of the following sensing or feedback features: impedance sensing to detect peritonitis, temperature sensing to detect peritonitis, bio-MEMS sensing to detect peritonitis, and glucose control for diabetes patients, wherein each sensing or feedback feature analyzes patient effluent fluid or fluid dwelling within a patient's peritoneal cavity. un u n e r i t o n e a l d i a l y s i s , s u c h a s a u t o m a t e d p e r i t o n e a l d i a l y s i s ( " " ) i s p r o v i d e d w i t h a n y o n e o r m o r e o r a l l o f t h e f o l l o w i n g s e n s i n g o r f e e d b a c k f e a t u r e s : i m p e d a n c e s e n s i n g t o d e t e c t p e r i t o n i t i s , t e m p e r a t u r e s e n s i n g t o d e t e c t p e r i t o n i t i s , b i o - s e n s i n g t o d e t e c t p e r i t o n i t i s , a n d g l u c o s e c o n t r o l f o r d i a b e t e s p a t i e n t s , w h e r e i n e a c h s e n s i n g o r f e e d b a
Absstract of: US2025213146A1
There is provided a glucose sensor system comprising: a transmitter (2) for containing a battery (212), the transmitter being for placement on top of patient skin; a transcutaneous connector (3) comprising at least one conductive path; and an implantable monolithic integrated circuit (I) for placement beneath the patient skin, wherein the implantable monolithic integrated circuit comprises a potentiostat and an electrochemical sensing element; wherein the potentiostat is electrically coupled to the transmitter (2) via the transcutaneous connector (3), and the electrochemical sensing element is configured to sense glucose concentration and generate an electrical signal representative of the glucose concentration, and wherein the potentiostat is electrically connected to the electrochemical sensing element.
Absstract of: US2025213145A1
A method for non-invasively estimating blood glucose for estimating a blood glucose value of a user by a computing device. The method includes receiving a plurality of electrocardiogram (ECG) waveforms of the user, extracting at least two first ECG features from each of the plurality of ECG waveforms of the user, respectively determining a first feature peak position corresponding to each of the first ECG features, calculating at least one peak distance between the plurality of the first feature peak positions, and estimating the blood glucose value of the user based on the peak distance. The first ECG features are selected from the group consisting of a P-wave, a Q-wave, an R-wave, an S-wave, a T-wave, and a U-wave. Furthermore, a computing device for non-invasively estimating blood glucose, a device for non-invasively measuring ECG signal, and a non-transitory computer readable storage medium are utilized for the method.
Absstract of: US2025213202A1
This invention provides a system and method to protect an artificial pancreas' sensor, infusion system, and alert systems from EMI/wireless attacks using a medical software or application, close the gap between sensor glucose and blood glucose, and build a non-invasive hypoglycemia and hyperglycemia false alarm detection scheme with the help of a wristband. This inventive method and system provides a more accurate blood glucose prediction. It comprises preprocessing the CGM readings with Kalman smoothing for sensor error correction improves the robustness of the BG prediction. In one or more embodiments, the inventive system and method uses one or more physiological information such as meal, insulin, aggregations of step count, and preprocessed CGM data. The invention provides a novel approach for leveraging the stacked LSTM based deep RNN model to improve the BG prediction accuracy. The invention provides a special circuits-Transduction Shield-to detect and correct the sensor errors caused by EMI attacks.
Absstract of: US2025213191A1
A continuous analyte monitoring system includes analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller is coupled to the analyte sensors and configured evaluate first samples of outputs of a first analyte sensor and second samples of outputs of a second analyte sensor to determine whether the first samples and the second samples indicate compression of the tissue. The controller compensates for the compression of the tissue with respect to the first samples. A force sensor may be used and may be positioned between a circuit board and a housing, the circuit board supported by supports providing preloading of the force sensor. A force deflector may be used to direct loads away from tissue holding the analyte sensors. A housing may have a flexible lower surface to reduce loading of the tissue.
Absstract of: US2025213147A1
Methods and devices include automated coaching for management of glucose states by receiving a user's glucose levels using a continuous glucose monitoring (CGM) device, determining a time in range (TIR) value, determining a TIR state, receiving a glucose variability (GV) value, determining a GV state, determining a starting state based on the TIR state and the GV state, determining that the starting state corresponds to a non-ideal state, generating an optimized pathway to reach an ideal state based on one or more account vectors such as addressing self-management behavior including food, activity, and medication use. The optimized pathway may further be based on computer detection and classification of significant events of interest over time.
Absstract of: US2025213155A1
The present disclosure relates to a body attachment unit for continuous blood glucose measurement, in which the body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without performing additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start point in time can be adjusted to an appropriate point in time according to the user's needs, and activation occurs in a stabilized state, thereby providing the body attachment unit allowing more accurate blood glucose measurement.
Absstract of: US2025213785A1
Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.
Absstract of: US2025213784A1
Systems and methods are provided for enabling and disabling insulin pumps in a multi-pump insulin pump system. For example, multiple pumps (e.g., patch pumps) may be rotated to deliver insulin to a user. In one example, one patch pump may be worn while another patch pump is charging. Once the battery of the patch pump worn by the user is depleted, a mobile device may cause the enabled pump in operation and worn by the user to send the latest pump settings and configuration data to the mobile device which will share the information with the disabled pump. The disabled pump will then update the pump settings based on this information and the mobile device may active the pump such that is now enabled for insulin delivery. The mobile device may also facilitate pairing between the patch pumps and a CGM device as they enabled for use and disabled.
Absstract of: US2025218600A1
Glucose forecasting systems and methods that include a minimally invasive scalp-worn behind-the-ear EEG device that includes first and second sensors. With an application on a personal device, analyzing the processed EEG signals with a trained forecasting model and forecasting future glucose levels, of the subject; causing the personal device to visually present on a display information that is indicative of the forecasted future glucose levels.
Absstract of: US2025218565A1
The present disclosure provides a technology capable of appropriately supporting improvement of an individual's lifestyle. The lifestyle improvement support system is provided with an acquisition device capable of acquiring from a target person at least their blood glucose level data, physical activity data, and dietary activity data, as well as a controlling device.
Absstract of: US2025218598A1
Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.
Absstract of: WO2025145062A1
Disclosed herein are system, method, and computer program product embodiments for calculating accurate doses for medication using improved user interface features that may be implemented as part of an application operating within a continuous glucose monitoring system. The disclosed interface provides an improved user experience when a medication delivery device is disconnected or does not have the ability to query the requisite data.
Absstract of: WO2025141541A1
Systems and methods are provided for enabling and disabling insulin pumps in a multi- pump insulin pump system. For example, multiple pumps (e.g., patch pumps) may be rotated to deliver insulin to a user. In one example, one patch pump may be worn while another patch pump is charging. Once the battery of the patch pump worn by the user is depleted, a mobile device may cause the enabled pump in operation and worn by the user to send the latest pump settings and configuration data to the mobile device which will share the information with the disabled pump. The disabled pump will then update the pump settings based on this information and the mobile device may active the pump such that is now enabled for insulin delivery. The mobile device may also facilitate pairing between the patch pumps and a CGM device as they enabled for use and disabled.
Absstract of: AU2023415787A1
The present invention provides a sensor applicator assembly for a blood glucose meter, comprising: an applicator; and a body attachment unit which is disposed in the applicator, and which is composed of a housing including an upper frame and a lower frame, wherein the lower frame has a recessed part formed along the entire circumferential section thereof.
Absstract of: US2019013091A1
User interfaces are needed to alert and inform a person suffering from diabetes or a healthcare provider of possible harmful changes in the patient's blood glucose level. An improved method is presented for issuing an alert regarding a glucose condition of a patient by a diabetes management system. For a given patient, their glucose condition is quantified and presented as a state on a display. Glucose conditions can also be prioritized for a plurality of patients and presented to a healthcare provider.
Absstract of: WO2025145024A1
Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.
Absstract of: WO2025140911A1
A method performed by a computer system for monitoring diabetes and comprising: a model explainability phase, comprising steps of: - collecting specific foot data from at least one sensor disposed at least within a shoe insole of a user, - collecting a plurality of trained machine learning models configured for decision-making in diabetes diagnosis based on a plurality of collected data, - based on the plurality of trained machine learning models, generating a plurality of specific machine learning models, said specific machine learning models being specified for decision-making in diabetes diagnosis based on the specific foot data, and a model reliability assessment phase, comprising steps of: - evaluating a reliability of each of the specific machine learning model based on neutrosophic sets and intuitionistic fuzzy sets, - based on the result of the evaluation step, selecting the optimized machine learning model for monitoring diabetes based on the specific foot data.
Absstract of: WO2025144547A1
A continuous analyte monitoring system includes analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller is coupled to the analyte sensors and configured evaluate first samples of outputs of a first analyte sensor and second samples of outputs of a second analyte sensor to determine whether the first samples and the second samples indicate compression of the tissue. The controller compensates for the compression of the tissue with respect to the first samples. A force sensor may be used and may be positioned between a circuit board and a housing, the circuit board supported by supports providing preloading of the force sensor. A force deflector may be used to direct loads away from tissue holding the analyte sensors. A housing may have a flexible lower surface to reduce loading of the tissue.
Nº publicación: WO2025145056A1 03/07/2025
Applicant:
TANDEM DIABETES CARE INC [US]
TANDEM DIABETES CARE, INC
Absstract of: WO2025145056A1
Disclosed herein are apparatuses and methods that account for exercise in closed loop insulin delivery systems. The apparatuses and methods disclosed herein address exercise-induced glucose level increases by reducing the target IOB within the closed loop. By reducing the target IOB, the algorithm responds less aggressively to pre-exercise food, and does not build up the IOB that could potentially contribute to undesirably low glucose levels once the exercise also begins lowering glucose levels. Following exercise, because the user's body will not immediately transition to a pre-exercise state, the algorithm will gradually transition back to the initial target IOB.
BOPI
Electronic site
